Currently, the design of amplifying mRNA cancer vaccines in the preclinical stage mainly involves the targeting of TAAs, including tyrosinase, pMEL17/gp100, gp75/tyrosinase-related protein (TRP)-1, MART-1/melan-A, and dopachrome tautomase/TRP-2 which are preferentially expressed in melanoma cells. Here, PMEL is linked to cancer.